Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Dec 4 2020

Full Issue

China Is Upbeat About Its Two Vaccines In Early-Stage Trials

Both produced strong immune responses, researchers said. News is on the United Nations' summit on COVID, Turkey's decision to start vaccinating soon and more.

Reuters: China's Clover Says Its COVID-19 Vaccines Trigger 'Strong Immune Responses' In Early Trial 

Two coronavirus vaccine candidates developed by China’s Clover Biopharmaceuticals triggered strong immune responses in an early-stage human trial and appeared to be safe, the company said on Friday. The vaccine candidates, one containing an adjuvant from GlaxoSmithKline and the other from Dynavax, induced strong immune responses including neutralizing antibodies and cell-mediated immunity in a Phase 1 clinical trial, Clover said. Adjuvants are ingredients that can boost immune responses. (12/4)

In other global developments —

Politico: U.N. Hosts The World’s Weirdest Summit On Covid-19

It took the United Nations General Assembly nine months to arrange a special session dedicated to discussing the Covid-19 pandemic. No one, not even the organizers, knew what to expect from the two-day virtual summit that kicked off Thursday. The prevailing mood so far has been one of head-scratching: about why the event took so long to organize, and what point there was in holding it now. (Heath and Paun, 12/3)

AP: UN Chief: Vaccine Can't Undo Damage From Global Pandemic

The U.N. chief warned Thursday that the social and economic impact of COVID-19 “is enormous and growing” and said it’s foolish to believe a vaccine can undo damage from the global pandemic that will last for years or even decades. Speaking to world leaders at the General Assembly’s first and mainly virtual special session on COVID-19, Secretary-General Antonio Guterres accused some countries he didn’t name of ignoring or rejecting the World Health Organization’s recommendations at the start of the crisis early this year, resulting in nations going in their own directions and the virus spreading “in every direction.” (Lederer, 12/4)

AP: Turkey Announces Vaccination Plan For Chinese CoronaVac

Turkey’s health minister has announced a plan to start using an experimental Chinese COVID-19 vaccine later this month amid a surge in infections and deaths. Fahrettin Koca had previously announced an agreement with China’s Sinovac Biotech for 50 million doses of CoronaVac, which is currently in late stage trials. Koca said in a statement late Wednesday that the first shipment of the vaccine will arrive in Turkey after Dec. 11. (Bilginsoy, 12/3)

The New York Times: E.U. Privacy Rule Would Rein In The Hunt For Online Child Sexual Abuse 

A rule scheduled to take effect on Dec. 20 would inhibit the monitoring of email, messaging apps and other digital services in the European Union. It would also restrict the use of software that scans for child sexual abuse imagery and so-called grooming by online predators. The practice would be banned without a court order. European officials have spent the past several weeks trying to negotiate a deal allowing the detection to continue. But some privacy groups and lawmakers argue that while the criminal activity is abhorrent, scanning for it in personal communications risks violating the privacy rights of Europeans. (Dance and Satariano, 12/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF